Proteomics International Laboratories (ASX:PIQ) has opened a clinical laboratory improvement amendments (CLIA) certified reference laboratory in Irvine, California, according to a Friday filing with the Australian bourse.
The company has secured both a California State License and the CLIA certification, allowing it to operate as a certified clinical laboratory within the US, the filing said.
The laboratory will initially offer the PromarkerD test, which predicts diabetes-related chronic kidney disease (DKD), and plans to expand with tests for esophageal cancer and endometriosis, the filing added.
The launch of PromarkerD, shown to predict DKD up to four years in advance, is expected in the second quarter, the company said.
The laboratory is designed for scalability, allowing Proteomics International to introduce additional diagnostic tests efficiently in the US market, the company added.
Shares of the company fell 8% in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。